Galena Biopharma to Present at NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference
January 11 2016 - 7:05AM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of targeted
oncology therapeutics that address major unmet medical needs, today
announced that Mark W. Schwartz, Ph.D., President and Chief
Executive Officer will present a corporate update at NobleCon12 -
Noble Financial Capital Markets’ Twelfth Annual Investor
Conference. The presentation will take place on Monday, January 18,
2015 at 2:30 p.m. ET in Sandpiper Bay, Florida.
The presentation will be webcast and available on the Investors
section of the Company's website at
http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed
to the development and commercialization of targeted oncology
therapeutics that address major unmet medical needs. Galena’s
development portfolio is focused primarily on addressing the
rapidly growing patient populations of cancer survivors by
harnessing the power of the immune system to prevent cancer
recurrence. The Company’s pipeline consists of multiple mid- to
late-stage clinical assets, including novel cancer immunotherapy
programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax
is currently in a pivotal, Phase 3 clinical trial with several
concurrent Phase 2 trials ongoing both as a single agent and in
combination with other therapies. GALE-301 is in a Phase 2a
clinical trial in ovarian and endometrial cancer and in a Phase 1b
given sequentially with GALE-302. For more information, visit
www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda SVP, Investor Relations & Corporate
Communications (925) 498-7709rbernarda@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024